I should like to review very briefly the various kinds of genetic damage that might be expected to occur from chemical mutagens, the time delay before such effects might be manifest, and something of the kind of impact that these might be expected to have on human well-being. I hardly need to add that this is an area where we know very little; we know enough to be apprehensive, but not enough to be at all certain.
My remarks will draw heavily from two recent reports on radiation effects, the National Academy of Sciences Report (1) and the United Nations Report (2) . In the area of radiation protection there are standards which are agreed to internationally and which form the basis of radiation protection policy. I suggest that in the area of chemical mutagenesis we can obtain considerable guidance from the older field of radiation mutagenesis. I 
Minor Effects
We know almost nothing about this category in man or other mammals, but in Drosophilta the most frequent kind of mutational event is a mutant whose effects are too small to be detected in the individual fly, but which cause a statistically detectable decrease in the probability of survival to adulthood, or in fertility.
The incidence of these per million live births, as given in the BEIR report (1) , is summarized in Table 1 . The category, "constitutional and degenerative diseases," is admittedly very uncertain. This number can be made to have almost any value by the appropriate choice of which diseases to include (who is free of all physical imperfections?). The number given includes most of the severe conditions thought to have some genetic basis and which are expressed in childhood or early adulthood. If there is an increase in nondisjunction or chromosome loss following some environmental chemical, the effect will begin the next generation, and virtually the whole effect will be in that one generation. This is because almost all aneuploidy leads to embryonic death, early postnatal death, or to some condition that reduces the net fertility to essentially zero.
Unbalanced rearrangements caused by chromosome breakage may be delayed by several generations, but most of the impact of the genetic damage is within the first halfdozen generations.
For more complexly inherited traits it is almost a pure guess, both as to the extent and the time of expression following the chemical influence.
I have been very sketchy in this review.
More details are available in the National Academy report (1) and especially in the United Nations report (2) . The area of greatest uncertainty is minor, quantitative effects. As I said earlier, in well studied organisms, especially Drosophilia, the most common known mutant type is one causing a minor effect on viability. One might think that mutants that are too mild to have a noticeable effect can be ignored. But there are two arguments in opposition to this view.
One is that what is not noticeable in Drosophitla may be very important to a human being. (You can't ask a fly where it hurts.) Also, the milder the effect the mutant has, the less is its probable effect on fertility; and therefore, the longer it will persist in the population. By affecting a larger number of persons to a mild degree, the overall impact of the mutant may be as great as if it affected a smaller number more severely. This becomes especially important if there are many such mutants, so that each person is afflicted with several; no one may mean much, but their cumulative effect may mean an appreciable impairment of some body function.
Most attempts to quantitate the effect of a mutation increase in man ignore this category. Since I have no idea how to quantify it, I will, too-but with the uneasiness that comes from the fear that we may well be ignoring the most important part.
It is clear that we have almost no quantitative information on how an increased mutation rate, whatever its cause, would affect human survival, health, and well-being. It is also clear that we could have a substantial increase in the mutation rate without knowing it. We are reasonably agreed that the effect of any increase in the mutation rate would be harmful, but how Alternatively, a compound that is -used exclusively for the treatment of a severe disease that is rare or that affects mainly people over 40 years of age might be highly mutagenic, but few would argue against its use if it were of great benefit.
What do we do if the chemical has a definite benefit to many and is found to be mutagenic? I think we have to have some sort of quantitative criterion. Ultimately we must try to balance benefit against risk, as is tried for x-rays and nuclear energy.
First we need some kind of estimate of the dose to the population. We need to know: (a) how large a fraction of the population would be exposed (b) the dosage (of course we are interested in the dose that reaches the reproductive cells), (c) the age and sex distribution of the dose. We would then try to compute something like the average genetically significant dose (GSD) to the population, as is done for radiation. By this we mean the gonad dose weighted by the expected number of children to be born. To do this we need to know age and sex-specific survival and fertility rates.
Given this information, it will still be some time before we are able to make any reasonable estimate of the risk. What do we do in the meantime? I suggest that we use radiation as a guideline.
Chemical Mutagens Assessed in Terms of Radiation Equivalents
How has the question been dealt with for radiation? In general there is an attempt to balance the cost against the benefit. Even though both factors to be weighed are very uncertain, it may be that the benefit is so great or so minute that even a very rough calculation of risk may suffice for a rational decision.
The most reliable criterion for setting radiation standards for the general population has been the background level of radiation. I think that despite numerous attempts to quantify the genetic risk, the most convincing argument we have the for the present radiation standards is that they are close to the natural background radiation.
The present standard for the general population is 170 mrem per year from all nonmedical, man-made causes. The average background radiation is about 100 mrem per year. It is generally believed, although the evidence is far from complete, that natural radiation accounts for only a minor fraction of the total human mutation rate. Therefore a doubling of the amount of radiation would double only that fraction of the mutation rate that is caused by natural radiation. Man has survived background radiation throughout his entire history and, although there is no reason to think that it has been good for him, the harm done by it has been something that he has been able to tolerate.
Therefore I suggest that we try to tie chemical mutagenesis in with radiation. I suggest that chemical mutagens be assessed in terms of roentgen equivalents, or a roentgen equivalent dose (RED). [I am pleased to see that Dr. Bridges (4) If we knew more, we could try to set environmental chemical standards so that the induced mutation rate would be less than some fraction (say, 10%o of the spontaneous mutation rate. That is, we would choose a concentration that in 30 years of exposure would produce a certain fraction of the spontaneous human mutation rate. However, we cannot make such a calculation now, for we know neither the human spontaneous mutation rate nor the effect of the mutagen.
So this kind of assessment cannot now be made yet. Until it can be, I suggest the radiation-equivalent concept as the best way of getting started in dealing with setting standards for chemicals that are slightly mutagenic, but otherwise of sufficient benefit that this appears to outweigh the risk.
I should like to end by acknowledging the help I have gotten from Dr. Seymour Abrahamson. Several of the ideas presented here are the result of discussions with him.
